RT info:eu-repo/semantics/article
T1 Nasal symptoms in asthmatic patients under treatment with anti-IL-5 monoclonal antibodies. A real-life cohort study
A1 Maza Solano, Juan
A1 Calvo Henríquez, Christian
A1 Alobid, Isam
A1 Álvarez Cendrero, Marta
A1 Palomares, Óscar
A1 Moreno Luna, Ramón
A1 Santos Pérez, Jaime
A1 González García, Jaime
A1 Sánchez Gómez, Serafín
K1 Asthma
K1 Asma
K1 Allergy
K1 Otorhinolaryngology
K1 Otorrinolaringologia
K1 Chronic diseases
K1 Enfermedades crónicas
K1 Respiratory organs - Diseases
K1 Respiratorio, aparato - Enfermedades
K1 Pneumology
K1 Neumología
K1 Nose - Diseases
K1 Nariz - Enfermedades
K1 Asthma - Treatment
K1 Asma - Tratamiento
K1 3207.01 Alergias
K1 3205.08 Enfermedades Pulmonares
AB Currently, some monoclonal antibodies (mAbs) are being studied for chronic rhinosinusitis with nasal polyps (CRSwNP). Three anti-IL-5 mAb: mepolizumab, reslizumab and benralizumab, have been tested through randomized clinical trials. In this real-life study, we aimed to describe the nasal effects of a cohort of asthmatic adults treated with anti-IL-5 mAb. Methods: We carried out an observational study in adults (≥18 years) on anti-IL-5 mAb treatment. Variables included ACT and SNOT−22 questionnaires, nasal polyps score, blood total IgE levels and blood eosinophil count. Results: Overall, 38 participants were included in the study; 19 patients received mepolizumab, 17 were treated with benralizumab and 2 patients were given reslizumab. There was a statistically significant difference in the ACT and SNOT−22 scores before and after mAb treatment. ACT score increased from 11.05 to 21.5 after treatment (p < 0.001). SNOT−22 decreased from 57 to 37.3 after treatment (p = 0.004). No statistically significant differences between mAb groups were observed regarding the ACT or the SNOT−22 (p = 0.775) response (p = 0.775). In addition, 60.53% of patients obtained a minimal clinically important difference (MCID) in SNOT−22. Conclusions: A significant clinical response based on SNOT−22 score evolution after anti-IL-5 mAb treatment was observed. This study also demonstrated that blood eosinophil count, rather than serum total IgE levels, is the best predictor of asthma symptom improvement, which was assessed through the ACT and SNOT−22 questionnaires.
PB MDPI
SN 2077-0383
YR 2022
FD 2022
LK https://uvadoc.uva.es/handle/10324/60263
UL https://uvadoc.uva.es/handle/10324/60263
LA eng
NO Journal of Clinical Medicine, 2022, Vol. 11, Nº. 23, 7056
NO Producción Científica
DS UVaDOC
RD 04-abr-2025